Edition:
India

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

81.99USD
8 Dec 2017
Change (% chg)

$1.09 (+1.35%)
Prev Close
$80.90
Open
$81.48
Day's High
$83.13
Day's Low
$81.21
Volume
314,897
Avg. Vol
438,008
52-wk High
$100.50
52-wk Low
$80.10

Select another date:

Mon, Nov 27 2017

BRIEF-Biomarin Sells Second Priority Review Voucher For $125 Mln

* BIOMARIN SELLS SECOND PRIORITY REVIEW VOUCHER FOR $125 MILLION

BRIEF-Biomarin reports Q3 loss $0.07/shr

* Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S

BRIEF-FDA grants Breakthrough Therapy Designation for BioMarin's gene therapy for hemophilia A

* FDA grants Breakthrough Therapy Designation for BioMarin's valoctocogene roxaparvovec (formerly BMN 270), an investigational gene therapy for hemophilia A

BRIEF-Biomarin Pharmaceutical: Increased board size from nine to ten members​

* Biomarin Pharmaceutical says ‍on September 28, 2017, board of directors of increased size of board from nine to ten members​ - SEC filing Source: (http://bit.ly/2yWOHiP) Further company coverage:

BRIEF-FDA not planning to hold advisory committee meeting for Biomarin's Pegvaliase BLA

* FDA not currently planning to hold advisory committee meeting for Biomarin's Pegvaliase Biologics License Application (BLA)

BRIEF-FDA accepts Biomarin's Pegvaliase Biologics License Application

* FDA accepts Biomarin's Pegvaliase Biologics License Application (bla) and grants priority review designation

BRIEF-BioMarin announces offering of $450 mln of 0.599 pct senior convertible notes

* BioMarin announces offering of $450 million of 0.599% senior subordinated convertible notes due 2024

BRIEF-Biomarin announces offering of $450 mln of senior subordinated convertible notes due 2024

* Biomarin announces offering of $450 million of senior subordinated convertible notes due 2024

BRIEF-BioMarin announces plans to progress both the 6e13vg/kg and 4e13 vg/kg doses of BMN 270, its investigational gene therapy for Hemophilia A, into phase 3 studies

* BioMarin announces plans to progress both the 6e13vg/kg and 4e13 vg/kg doses of BMN 270, its investigational Gene Therapy For Hemophilia A, into phase 3 studies

BRIEF-Sarepta and Biomarin report execution of global settlement

* Sarepta Therapeutics and Biomarin Pharmaceutical Inc. Announce execution of a global settlement and a license agreement resolving exon skipping patent litigation

Select another date: